Last night Sen. John McCain's office announced the maverick politician had been diagnosed with a type
of aggressive brain cancer called glioblastoma.
In collaboration with the Vall Hebrón Oncology Institute (VHIO), they are now focusing on binding a peptide to a therapeutic antibody to treat glioblastoma — the
most aggressive brain cancer in adults.
Together with clinical researchers, they are preparing treatments for glioblastoma — the most
aggressive brain cancer in adults — , Friedreich's Ataxia — a hereditary neurodegenerative disease — , and a type of paediatric brain cancer.
«Studies help shed light
on aggressive brain cancer: One study shows how glioblastomas quickly evolve, the other points to a promising type of therapeutic.»
There is at least one approved device and scores of experimental treatments being tested that could improve the odds of longer - term survival for patients with the type of
extremely aggressive brain cancer afflicting U.S. Sen. John McCain.
«Encouraging results for patients
with aggressive brain cancer: New clinical study shows promising survival rates for patients with glioblastomas while reducing burden on health resources.»
We started our research when Facebookâ $ ™ s Year In Review feature first juxtaposed his daughterâ $ ™ s faceâ $ Šâ $» â $ Šhis daughter Rebecca, who died
of aggressive brain cancer on her sixth birthdayâ $ Šâ $» â $ Šwith balloons and partiers.
Despite current treatment strategies, the median survival for patients with the
most aggressive brain cancer — called glioblastoma, is 15 months.
«Metabolic molecule drives growth of
aggressive brain cancer.»
Temodar was originally approved in 1999 as a capsule to fight
an aggressive brain cancer, glioblastoma multiforme.
«Health care and the research needed — particularly in cancer, as well as in other areas — is what drove me to Congress,» Sestak told WHYY, noting his 8 - year - old daughter's successful fight 5 years ago against
an aggressive brain cancer.
Researchers have used low - intensity, intermediate - frequency electric fields to combat
an aggressive brain cancer known as glioblastoma multiforme (GBM).
A research team led by Christine Brown, Ph.D., and a clinical team headed by Behnam Badie, M.D., has received a $ 12.8 million grant from the CIRM to fund a phase 1 chimeric antigen receptor (CAR) T cell trial targeting
an aggressive brain cancer called malignant glioma, which includes glioblastoma.
Glioblastoma Moon Shot Our ambitious effort to quadruple the five - year survival rate for
this aggressive brain cancer, from 10 % to 40 %, in the next decade.